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 PROGESTERONE VAGINAL RING  
SAFE FOR MOTHERS AND BABIES 
  
The Progesterone Vaginal Ring 
(PVR) is a vaginal ring which 
contains progesterone and can 
prevent pregnancy. It has been 
proven to be a safe and effective 
method of contraception for 
lactating women. 
 
The PVR is safe for mothers and their infants because it 
relies on the mother breastfeeding and there are no effects 
on health. It works as a contraceptive by: 
• Reinforcing the inhibitory effect of breastfeeding on 
ovulation. 
• Extending postpartum amenorrhea. 
 
 
PVR DOES NOT AFFECT BREASTFEEDING 
 
A nursing mother will be able to breastfeed without 
disruption. She will be able to nurse just as much and for as 
long as she would have without the PVR. The natural 
hormone progesterone that is in the ring does not affect the 
volume of breast milk a lactating woman produces or the 
frequency of breastfeeding (Nath and Sitruk-Ware 2010). On 
the contrary, the efficacy of the method depends on 
continued breastfeeding with a minimum of four feeding 
episodes per day.  
 
A clinical trial comparing the PVR and the IUD found that 
women on the PVR breastfed for the same amount of time or 
longer than those on the IUD. Reasons for weaning were 
similar in both groups (Sivin et al. 1997). 
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EFFECT ON INFANT HEALTH 
 
The PVR has been shown to have no effects on the 
growth or development of infants whose mothers were 
using it.  
 
Clinical trials have demonstrated that infants of mothers 
who were using the PVR did not differ in growth and 
development than those whose mothers were using the 
copper IUD (Nath and Sitruk-Ware 2010). 
• The weights of infants of mothers using the PVR 
were similar to those of whose mothers were using 
the IUD over the first year of life. Similar infant 
weight increases over the first year of life have 
been reported by other clinical studies as well 
(Massai et al. 2005).  
• The dose of the hormone delivered by the ring is 
lower than what an ovulating woman would 
normally secrete in her blood. Therefore, the 
exposure an infant has to the hormone is far lower 
than what it would be if its mother had resumed 
her regular menstrual cycles.  
• When mothers use contraception, babies typically 
get very low levels of progesterone from breast 
milk. For example, estimates indicate that babies 
of mothers using implants receive about 5 
mcg/day of progesterone which is considerably 
lower than the European Medicines Agency (EMA) 
stipulated maximum intake of 150 mcg per day. 
• Less than 10 percent of progesterone is bio-
available to babies due to the low levels of 
progesterone in breast milk and its short half-life 
after passing through the baby’s digestive tract 
where the hormone is quickly eliminated (Nath and 
Sitruk-Ware 2010; Massai et al. 2000). 
EFFECT ON SEXUAL PARTNERS 
 
Sexual partners have limited exposure to the 
progesterone in the ring and hence are not affected by it. 
At most, some men may feel the presence of the ring. 
Users have reported that the ring has not had any effect 
on their or their partner’s sexual pleasure (Nath and 
Sitruk-Ware 2010).  
 
EXPANDING CONTRACEPTIVE OPTIONS 
 
In 2015, the PVR has been added to the World Health 
Organization’s (WHO) Essential Medicines List (EML) and 
Medical Eligibility Criteria (MEC) for Contraceptive Use 
guidance for providers.  
 
 
SUMMARY 
 
The PVR is an effective and safe contraceptive for 
mothers, their babies, and their sexual partners. This 
method vastly expands the range of contraceptive 
choices available for nursing women.  
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